KENILWORTH, N.J.–(BUSINESS WIRE) July 16, 2020 — Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has accepted for priority review the New Drug Application (NDA)…Original Article
FDA Grants Priority Review to Merck’s New Drug Application for Vericiguat
